Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a2026 Fierce 50Breakthrough honoree by Fierce Pharma, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 ...

Compass Pathways stays a Buy, but Eli Lilly’s AtaiBeckley deal raises competition and funding risks. Click to get key ...

CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we announced today" as a key update, citing the completion of enrollment for the COMP006 Phase III trial ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Read ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported ...

Compass Pathways stock plunged Tuesday, even as the London-based psychedelic-drug developer said a strong dose of its psilocybin-based drug helped reduce depression in treatment-resistant patients ...

Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...

While about 100 clinical trials focused on psychedelic compounds are chugging along in the regulatory pathway to examine the potential the drugs have to treat illnesses like depression and alcoholism, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Ca ...